

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



Abbisko Cayman Limited
和譽開曼有限責任公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that CSF-1R inhibitor ABSK021 of Abbisko Therapeutics Co., Ltd., a subsidiary of the Company, has been granted Phase III clinical trial approval by the National Medical Products Administration of the People’s Republic of China.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK021 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, October 25, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; Dr. Xia Gavin Guoyao and Ms. Tang Yanmin as non-executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.

Abbisko Therapeutics obtained pivotal Phase III clinical trial approval for CSF-1R inhibitor ABSK021 from the CDE of NMPA

25 October 2022, Shanghai – Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**” hereafter) today announced that its CSF-1R inhibitor ABSK021 has been approved by the Center for Drug Evaluation (“**CDE**”) of the National Medical Products Administration of the People’s Republic of China (“**NMPA**”) for a randomized, double-blind, placebo-controlled and multicenter Phase III clinical study in patients with tenosynovial giant cell tumor (“**TGCT**”). ABSK021 is the first small molecule inhibitor approved for Phase III clinical trial among all drug candidates in the Company’s pipeline, and the first highly selective CSF-1R inhibitor developed by a Chinese company that has entered Phase III clinical trial.

ABSK021 is a novel, orally available, highly selective and highly potent small molecule CSF-1R inhibitor that is independently developed by Abbisko Therapeutics. In July 2022, ABSK021 was granted the breakthrough therapy designation by the CDE of NMPA for the treatment of TGCT that is not amenable to surgery. A number of studies have shown that blocking the CSF-1/CSF-1R signaling pathway could effectively modulate and change macrophage functions, and potentially treat many macrophage-dependent human diseases.

Abbisko Therapeutics has completed a Phase Ia dose escalation study for ABSK021 in the U.S., and has a Phase Ib multi-cohort expansion trial ongoing in both the U.S. and China. In addition to TGCT indication, Abbisko Therapeutics is actively exploring the potential of ABSK021 in treating many types of solid tumors in clinic, and has collaborated with Sperogenix (Shanghai) MedTech Co., Ltd. in exploring its potential for treating amyotrophic lateral sclerosis and other central nervous system diseases. As of the date of this press release, no highly selective CSF-1R inhibitor has been approved in China.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), is an oncology focused biopharmaceutical company founded in Zhangjiang, Shanghai, dedicated to discovering and developing innovative medicines to treat unmet medical needs in China and around the world. The company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built up an extensive pipeline of 15 innovative small molecule programs primarily focused on precision oncology and immuno-oncology, including six clinical stage assets and nine pre-clinical stage assets. As of today, Abbisko Therapeutics has received 14 IND or clinical trial approvals in four countries and regions.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.